TScan Therapeutics (NASDAQ:TCRX) Stock Price Down 11.9% – Here’s What Happened

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) dropped 11.9% during trading on Monday . The stock traded as low as $1.84 and last traded at $1.85. 339,391 shares traded hands during mid-day trading, an increase of 10% from the average session volume of 308,876 shares. The stock had previously closed at $2.10.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Monday, December 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Price Performance

The firm has a market cap of $98.74 million, a P/E ratio of -1.75 and a beta of 0.87. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company’s 50-day moving average is $2.49 and its two-hundred day moving average is $4.10.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TCRX. China Universal Asset Management Co. Ltd. acquired a new position in TScan Therapeutics during the fourth quarter valued at approximately $32,000. Prudential Financial Inc. bought a new position in shares of TScan Therapeutics in the 4th quarter valued at $32,000. ProShare Advisors LLC acquired a new position in shares of TScan Therapeutics during the 4th quarter worth $40,000. Wells Fargo & Company MN lifted its position in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in TScan Therapeutics in the fourth quarter valued at about $59,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.